ArticleDiscover oncology2026
Spatial heterogeneity of malignant molecular markers in glioma revealed by stereotactic biopsy.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo investigate the spatial distribution of key malignant molecular markers in glioma using MRI-guided stereotactic biopsies for tissue validation. MATERIALS AND
methodsThirty-seven patients with newly suspected gliomas underwent preoperative magnetic resonance imaging (MRI) followed by MRI-guided stereotactic biopsy and subsequent open craniotomy. Using preoperative MRI (T2-weighted imaging [T2WI]/fluid-attenuated inversion recovery [FLAIR] and contrast-enhanced T1WI), each tumor was radiologically subdivided into core, middle, and peripheral regions. Representative tissues from these regions were obtained via stereotactic biopsy. Immunohistochemistry (IHC) was performed to detect the expression of Ki67, ZEB1, NOTCH1, and HIF-1α.
resultsThe expression levels of Ki67, ZEB1, NOTCH1, and HIF-1α were positively correlated with increasing glioma grade (Kruskal-Wallis test, all P < 0.05).A significant spatial gradient was observed for Ki67 (P < 0.001), ZEB1 (P < 0.001), HIF-1α (P < 0.001), and NOTCH1 (P = 0.001) expression across the core, middle, and peripheral regions (Friedman test). Post-hoc pairwise comparisons confirmed the most pronounced difference was between the core and periphery for all markers (all P < 0.001).
conclusionsThe expression of Ki67, ZEB1, NOTCH1, and HIF-1α is closely associated with the malignant grade of gliomas and exhibits a conserved "core-to-periphery" decreasing gradient. The tumor core appears to be the molecular epicenter of aggressive phenotypes. These findings underscore the importance of targeting the radiologic core for diagnostic biopsy to avoid under-grading and suggest that spatial heterogeneity should be considered in therapeutic planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.